Published in Am J Med on May 01, 1991
Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet (1999) 4.16
Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet (1998) 1.41
Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer (2008) 1.18
The genetic basis of Muir-Torre syndrome includes the hMLH1 locus. Am J Hum Genet (1996) 1.07
Sebaceous gland tumors and internal malignancy in the context of Muir-Torre syndrome. A case report and review of the literature. World J Surg Oncol (2006) 1.03
Muir-Torre syndrome: a variant of the cancer family syndrome. J Med Genet (1994) 0.97
Early onset sebaceous carcinoma. Diagn Pathol (2011) 0.94
Paraneoplastic dermatological manifestation of gastrointestinal malignancies. World J Gastroenterol (2009) 0.94
Sebaceous carcinoma of the skin of the breast: a case report. J Med Case Rep (2008) 0.92
Extraocular sebaceous carcinoma mimicking benign sebaceous cyst. BMJ Case Rep (2013) 0.91
Extraocular sebaceous carcinoma: a series of three cases with varied presentation. Dermatol Pract Concept (2012) 0.88
Mammary cancer susceptibility: human genes and rodent models. Mamm Genome (2007) 0.88
New facial papules in a 66-year-old woman with bladder cancer. J Am Acad Dermatol (2014) 0.86
More than just skin deep: faciocutaneous clues to genetic syndromes with malignancies. Oncologist (2012) 0.86
[Female patient with Muir-Torre syndrome]. Ophthalmologe (2010) 0.82
Periocular sebaceous gland carcinoma: A comprehensive review. Saudi J Ophthalmol (2013) 0.81
Multifocal metastasizing extra-ocular facial sebaceous carcinoma as diagnostic challenge: case report and systematic review. J Maxillofac Oral Surg (2013) 0.80
Locally aggressive and multicentric recurrent extraocular sebaceous carcinoma: case report and literature review. Eplasty (2013) 0.79
Simultaneous Muir-Torre and Turcot's syndrome: A case report and review of the literature. Surg Neurol Int (2013) 0.77
Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment? Biomed Res Int (2015) 0.75
Clown nose: a case of disfiguring nodular squamous cell carcinoma of the face. BMJ Case Rep (2014) 0.75
Should all excised surgical specimens be examined microscopically? A case report. Cases J (2010) 0.75
Unusual presentation of metastatic sebaceous carcinoma and its response to chemotherapy: is genotyping a right answer for guiding chemotherapy in rare tumours? Curr Oncol (2015) 0.75
Ovarian Sex-cord Tumour with Peutz-Jeghers Polyp and Giant Keratoacanthoma. Med J Armed Forces India (2011) 0.75
Expression of retinoic acid-binding proteins and retinoic acid receptors in sebaceous cell carcinoma of the eyelids. BMC Ophthalmol (2015) 0.75
Muir-Torre syndrome in a haemodialysis patient. Clin Kidney J (2013) 0.75
Muir-Torre Syndrome Presenting as Sebaceous Adenocarcinoma and Invasive MSH6-Positive Colorectal Adenocarcinoma. Case Rep Oncol (2016) 0.75
Usefulness of PET/CT for early detection of internal malignancies in patients with Muir-Torre syndrome: report of two cases. Surg Case Rep (2017) 0.75
The liver: another organ involved in Muir Torre syndrome? Fam Cancer (2012) 0.75
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Mycosis fungoides and Sezary syndrome. Blood (1996) 2.15
Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol (1994) 2.11
Sweet's syndrome and cancer. Clin Dermatol (1993) 1.88
Systemic sclerosis. J Am Acad Dermatol (1993) 1.81
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71
Nevus with cyst. A report of 93 cases. Am J Dermatopathol (1993) 1.68
Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol (1988) 1.66
Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol (2000) 1.62
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood (1995) 1.52
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
Expression of the human hematopoietic progenitor cell antigen CD34 in vascular and spindle cell tumors. J Cutan Pathol (1993) 1.47
Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A (1985) 1.47
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest (1993) 1.43
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 1.43
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology (1985) 1.41
Chronic myelogenous leukemia: a concise update. Blood (1993) 1.40
Herpes simplex virus infections and cimetidine therapy. J Am Acad Dermatol (1988) 1.39
Sweet syndrome in patients with solid tumors. Cancer (1993) 1.38
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol (1988) 1.36
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol (2012) 1.35
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol (1995) 1.30
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med (1991) 1.28
Tripe palms and malignancy. J Clin Oncol (1989) 1.27
Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood (1998) 1.24
BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget (2013) 1.20
Sweet's syndrome and malignancy. Am J Med (1987) 1.18
Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood (1987) 1.18
A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med (1990) 1.17
Muir-Torre syndrome. Dermatol Clin (1995) 1.17
2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood (1994) 1.14
Molluscum contagiosum in patients with acquired immunodeficiency syndrome. Arch Ophthalmol (1987) 1.12
Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer (1991) 1.11
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res (1985) 1.10
RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol (1999) 1.09
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer (2012) 1.09
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med (1993) 1.08
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer (2013) 1.06
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia (2003) 1.05
KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Leukemia (1995) 1.05
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest (1994) 1.03
Differential expression of p21ras gene products among histological subtypes of fresh primary human lung tumors. Cancer Res (1986) 1.02
Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer (1991) 1.01
Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol (1999) 0.99
Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. Cancer (1995) 0.98
Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma (1997) 0.97
Coma blisters: report and review. Cutis (1990) 0.97
Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer (1996) 0.97
Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med (1995) 0.95
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood (1991) 0.95
The thumbprint sign: rapid diagnosis of disseminated strongyloidiasis. J Am Acad Dermatol (1990) 0.95
Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol (2012) 0.95
Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res (1993) 0.94
Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med (1997) 0.94
Benign rheumatoid nodules in a woman with chronic lymphocytic leukaemia and borderline lepromatous leprosy. Ann Rheum Dis (1993) 0.94
Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res (1987) 0.93
Pregnancy-associated Sweet's syndrome: world literature review. Obstet Gynecol Surv (1993) 0.93
Tripe palms and cancer. Clin Dermatol (1993) 0.92
Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. Am J Ophthalmol (2001) 0.91
Muir-Torre syndrome in patients with hematologic malignancies. Am J Hematol (1992) 0.91
Atrophia maculosa varioliformis cutis. Report of two cases and review of the literature. J Am Acad Dermatol (1994) 0.91
Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. Cancer Res (1999) 0.91
The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res (2001) 0.91
Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. J Interferon Cytokine Res (1995) 0.91
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann Oncol (2013) 0.91
Mucocutaneous paraneoplastic syndromes. Semin Oncol (1997) 0.90
Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta. Exp Hematol (1991) 0.90
Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol (1997) 0.89
Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J Exp Med (1986) 0.89
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors. Invest New Drugs (2014) 0.89
GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia (1998) 0.89
Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol (1986) 0.89
Miscellaneous genodermatoses: Beckwith-Wiedemann syndrome, Birt-Hogg-Dube syndrome, familial atypical multiple mole melanoma syndrome, hereditary tylosis, incontinentia pigmenti, and supernumerary nipples. Dermatol Clin (1995) 0.89
Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia (1997) 0.89
Hair casts or pseudonits. JAMA (1977) 0.88
Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood (1992) 0.88
High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma (1998) 0.88
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs (2013) 0.87
Acute febrile neutrophilic dermatosis. Am Fam Physician (1989) 0.87
Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol (2011) 0.87
Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol (1996) 0.87
Surgical amelioration of Dercum's disease: a report and review. J Dermatol Surg Oncol (1989) 0.87
A computer-assisted technique for 24-hour esophageal monitoring. Dig Dis Sci (1982) 0.86
Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. Cancer (1988) 0.86
Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leuk Res (1995) 0.85
Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood (1996) 0.85
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol (2013) 0.85
Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res (1986) 0.85
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol (2011) 0.84
Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol (1988) 0.84
Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet (1987) 0.84
Extracutaneous manifestations of Sweet's syndrome: steroid-responsive culture-negative pulmonary lesions. Am Rev Respir Dis (1992) 0.84
Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. J Intern Med (1993) 0.84
Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients. J Clin Oncol (1986) 0.84
Body composition and survival in the early clinical trials setting. Eur J Cancer (2013) 0.84